Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.02 (-3.25%)
Close on Nov 18, 2026Market cap $803.68KP/E –Yield –
Aptevo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aptevo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$26.89M. For fiscal 2025 it was -$26.31M. The highest annual figure on record is -$21.40M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.31M | – |
| FY2024 | Dec 31, 2024 | -$24.60M | – |
| FY2023 | Dec 31, 2023 | -$28.88M | – |
| FY2022 | Dec 31, 2022 | -$28.64M | – |
| FY2021 | Dec 31, 2021 | -$21.40M | – |
| FY2020 | Dec 31, 2020 | -$27.49M | – |
| FY2019 | Dec 31, 2019 | -$40.96M | – |
| FY2018 | Dec 31, 2018 | -$51.67M | – |
| FY2017 | Dec 31, 2017 | -$53.95M | – |
| FY2016 | Dec 31, 2016 | -$138.77M | – |
| FY2015 | Dec 31, 2015 | -$61.10M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.84M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.02M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.82M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.62M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.94M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.90M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.44M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.13M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.50M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.82M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.35M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.13M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$90.53M | – |
See a number that looks wrong?